{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:57:42Z","timestamp":1774684662115,"version":"3.50.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Relugolix is the newest form of androgen deprivation therapy (ADT) approved for prostate cancer. However, as an oral drug, several real-world concerns exist, particularly medication compliance, safety with other androgen receptor-targeted agents, and financial burden to patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A single institution retrospective chart review was conducted evaluating all patients who were prescribed relugolix for any prostate cancer indication from January 1, 2021 to January 31, 2022. Demographic data, cardiac risk factors, concomitant therapy usage, and PSA\/testosterone levels, were abstracted from the chart review. Adverse effects were obtained by examining progress notes. Compliance was assessed by clinic notes as well as prescription fills by specialty pharmacy records. The reasons patients did not fill or discontinued the medication were noted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Hundred and one patients were prescribed relugolix, and 91 patients consented to research. Seventy-one (78%) patients filled the prescription to relugolix, with a median follow-up of 5\u2009months. Prescription fill data were available for 45 (63%) patients, with 94% of days covered. The most commonly reported reason not to fill was cost at 50%. Sixty-six (93%) patients reported never missing a dose. PSA levels were available in 71 (100%) patients with 69 (97%) showing stable or improved PSA. Testosterone levels were available in 61 (86%) of patients, which showed 61 (100%) stable or successful castration. Twenty-four (34%) patients used relugolix in combination. No new major safety signals were seen in combination therapy. Nineteen (27%) patients had switched to another form of ADT. Fifteen of these (79%) felt similar or better on relugolix therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Compliance with relugolix seemed acceptable. No major new safety signals were seen, even in combination. Among patients who switched therapy, most tolerated relugolix similarly or better than the previous form of ADT. The cost was a major reason for patients not initiating and for discontinuing therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad036","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T19:37:54Z","timestamp":1678304274000},"page":"699-705","source":"Crossref","is-referenced-by-count":16,"title":["A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-019X","authenticated-orcid":false,"given":"Saro","family":"Kasparian","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center , Duarte, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center , Duarte, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni-Chun","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Biostats, City of Hope Comprehensive Cancer Center , Duarte, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joycelynne","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Biostats, City of Hope Comprehensive Cancer Center , Duarte, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumanta","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center , Duarte, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung","family":"Lyou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Providence St Jude Medical Center , Fullerton, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-298X","authenticated-orcid":false,"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center , Duarte, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"issue":"3","key":"2023080322083165500_CIT0001","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urology.2009.08.008","article-title":"Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare","volume":"75","author":"Oh","year":"2010","journal-title":"Urology."},{"issue":"382","key":"2023080322083165500_CIT0002","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","author":"Shore","year":"2020","journal-title":"N Engl J Med."},{"issue":"1","key":"2023080322083165500_CIT0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1756287212461048","article-title":"Experience with degarelix in the treatment of prostate cancer","volume":"5","author":"Shore","year":"2013","journal-title":"Ther Adv Urol"},{"issue":"11","key":"2023080322083165500_CIT0004","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"issue":"14","key":"2023080322083165500_CIT0005","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.2165\/10484080-000000000-00000","article-title":"Degarelix","volume":"69","author":"Frampton","year":"2009","journal-title":"Drugs"},{"issue":"5","key":"2023080322083165500_CIT0006","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.eururo.2009.11.029","article-title":"Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics","volume":"57","author":"Tombal","year":"2010","journal-title":"Eur Urol."},{"key":"2023080322083165500_CIT0007","article-title":"Comparison of the impact of degarelix and leuprolide on the health-related quality of life of patients with prostate cancer: results of a 12-month phase III clinical trial","author":"Marc Gittelman","year":"2011"},{"key":"2023080322083165500_CIT0008","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12894-015-0116-4","article-title":"Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon\u00ae registry","volume":"15","author":"Geiges","year":"2015","journal-title":"BMC Urol."},{"issue":"12","key":"2023080322083165500_CIT0009","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1210\/jc.2015-2770","article-title":"Medical castration using the investigational oral gnrh antagonist TAK-385 (relugolix): phase 1 study in healthy males","volume":"100","author":"MacLean","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"Suppl 2","key":"2023080322083165500_CIT0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/jco.2016.34.2_suppl.200","article-title":"Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts)","volume":"34","author":"Saad","year":"2016","journal-title":"JCO"},{"key":"2023080322083165500_CIT0011","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jval.2021.04.172","article-title":"PCN80 Estimating the difference in annual out-of-pocket costs for relugolix and leuprolide for medicare patients with metastatic prostate cancer","volume":"24","author":"Borrelli","year":"2021","journal-title":"Value Health."},{"issue":"2","key":"2023080322083165500_CIT0012","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3322\/caac.21443","article-title":"The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J Clin."},{"issue":"7","key":"2023080322083165500_CIT0013","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/10781552211035368","article-title":"Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer","volume":"28","author":"Feral","year":"2022","journal-title":"J Oncol Pharm Pract."},{"issue":"16","key":"2023080322083165500_CIT0014","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the pronounce randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/699\/51034852\/oyad036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/699\/51034852\/oyad036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T22:09:50Z","timestamp":1691100590000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/8\/699\/7072750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,3,8]]},"published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad036","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,3,8]]}}}